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ABSTRACT
We demonstrated previously that the cytosine
deaminase APOBEC3G inhibits retrotransposition
of two active murine endogenous retroviruses,
namely intracisternal A-particles (IAP) and MusD, in
an ex vivo assay where retrotransposition was
monitored by selection of neo-marked elements.
Sequencing of the transposed copies further dis-
closed extensive editing, resulting in a high load
of G-to-A mutations. Here, we asked whether this
G-to-A editing was associated with an impact of
APOBEC3G on viral cDNA yields. To this end, we
used a specially designed quantitative PCR method
toselectivelymeasurethecopynumberoftransposed
retroelements, in the absence of G418 selection.
We show that human APOBEC3G severely reduces
the number of MusD and IAP transposed cDNA
copies, with no effect on the level of the intermediate
RNA transcripts. The magnitude of the decrease clo-
sely parallels that observed when transposed copies
are assayed by selection of G418-resistant cells.
Moreover, sequencing of transposed elements
recovered by PCR without prior selection of the
cells reveals high-level editing. Using this direct
method with a series of cytosine deaminases, we
further demonstrate a similar dual effect of African
green monkey APOBE3G, human APOBEC3F and
murine APOBEC3 on MusD retrotransposition, with
a distinct extent and site specificity for each editing
activity. Altogether the data demonstrate that cyto-
sine deaminases have a protective effect against
endogenous retroviruses both by reducing viral
cDNA levels and by introducing mutations in the
transposed copies, thus inactivating them for
subsequent rounds of retrotransposition. This dual,
two-step effect likely participates in the efficient
defense of the cell genome against invading endoge-
nous retroelements.
INTRODUCTION
Since they entered living species millions of years ago, mobile
genetic elements have profoundly shaped the genomes of all
living organisms, via insertional mutagenesis and subsequent
DNA rearrangements (1–7). In mammals, most mobile ele-
ments are retrotransposons, which account for >45% of the
human and murine genomic DNA (8,9). They can be grouped
along two main classes: the well-characterized long inter-
spersed nuclear elements (LINE), which account for  30%
of the genome, and the long terminal repeat (LTR) retrotrans-
posons (or endogenous retroviruses), which are closely related
to infectious retroviruses. Most of these endogenous retro-
viruses, accounting for nearly 10% of the murine or human
genome, have lost a replication capacity due to the accumula-
tion of inactivating mutations, but several, including some mur-
ine intracisternal A-particles (IAP) and MusD sequences, are
still mobile (10,11). These elements move by an intracellular
copy and paste process involving an RNA intermediate, its
reverse transcription and the integration of the resulting
proviral DNA by the retrotransposon-encoded RNA-dependent
DNA polymerase and integrase, respectively (Figure 1A).
In fact, the requirement for genome stability has led eukary-
otes to adopt several strategies to restrict the proliferation
of transposable elements. These include transcriptional silenc-
ing through DNA methylation and/or chromatin structure
modiﬁcations (12–15), post-transcriptional silencing via
RNA interference (16–21) and, as shown recently, mutational
inactivation of the elements, in the course of their retrotrans-
position cycle, by cellular cytosine deaminases (22–24).
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doi:10.1093/nar/gkl054The cytosine deaminase family comprises numerous mem-
bers including, in humans, AID, APOBEC1, APOBEC2, the
APOBEC3A-G group and the recently discovered APOBEC4
(25–27). These enzymes can deaminate cytosine to uracil
within DNA and/or RNA molecules, depending on the family
member (28), and some of them have known physiological
functions [reviewed in Refs. (29–31)]. APOBEC1, the ﬁrst
discovered APOBEC protein, is the catalytic component of
the complex that edits the apolipoprotein B (APOB) mRNA
by deaminating C
6666 to U, thereby creating a premature stop
codon and leading to the production of a truncated form of the
apolipoprotein B lipid-transport protein in gastrointestinal
tissues (32–34). AID (activation-induced deaminase) plays a
role in the adaptative humoral immune system by initiating
immunoglobulin gene diversiﬁcation (somatic hypermutation,
gene conversion and class switch recombination), but its
precise mechanism of action, i.e. whether it acts through
RNA editing or genomic DNA deamination, is still a matter
of debate [for reviews see (35,36) and references therein].
APOBEC3G, the most extensively studied member of the
APOBEC family, and APOBEC3F restrict retroviral
infections: they convert cytosine to uracil in the nascent
single-stranded retroviral cDNA during reverse transcription
(37,38), resulting in G-to-A hypermutations in the proviral
DNA plus strand (39–45). Although APOBEC3G acts during
the early phase of the retroviral life cycle, antiviral activity is
observed only if APOBEC3G is expressed in the cell in which
the virion is produced (29,40,46–49). Primate lentiviruses
counteract this anti-retroviral activity by expressing the retro-
viral ‘Vif’ protein that prevents APOBEC3G incorporation
into virions, primarily by inducing its degradation via the
proteasome (50–58). The physiological roles of APOBEC2,
of APOBEC4 and of other members of the APOBEC3 group
are still unknown.
Previously, we demonstrated that human APOBEC3G
(hA3G) and murine APOBEC3 (mA3) restrict retrotransposi-
tion of mammalian endogenous retroviruses, with evidence for
‘traces’ of this mutagenic activity as G-to-A substitutions
within the genomic copies of some of these elements (22).
This activity most probably corresponds to a primary function
Figure 1. Rationale of the retrotransposition assay. (A) Schematic representation of the retrotransposition assay and experimental procedure for detection of
retrotransposition.Aretroelementmarkedwiththeneoreportergenedrivenbyitsownpromoter(Pr)andplacedinbackwardorientation(grayboxes)isintroducedby
transfectionintoHeLacells,togetherwithorwithoutanAPOBECexpressionvector.Theneogeneisrenderedinactivebythepresenceofaforwardintron,whichis
splicedoutoftheRNAintermediate,resultinginafunctionalgeneafterreversetranscriptionandintegration,allowingdetectionofretrotransposition.CellRNAand
DNA are extracted before G418 selection, as indicated. (B) Structure of the neo gene in the marked elements before and after retrotransposition, with the specific
primersusedforquantitativePCRanalysisandthesizeoftheexpectedPCRfragmentsindicated.(C)QuantitativePCRanalysisofretrotransposedmarkedelements:
(upper) ethidium bromide-stained agarose gel of the PCR products obtained using the primers shown in (B) and cellular DNA from Hela cells transfected with a
marked IAP, with the 643 bp fragment specific for the retrotranscribed spliced copies and the 725 bp fragment for the non-transposed parental copies indicated;
(lower) plot of the intensity of the 643 bp fragment against PCR cycle number; inset, linear fit using a semi-log scale, yielding an increment value per cycle of 1.75.
The725bpband,aswellasotherspuriousbands(e.g. 0.4and 0.9kb),wereofvariableintensitydependingontheexperiments,sometimesbeinghardlydetectable
(see text and Figure 2). The presence of such parasite bands clearly illustrates why standard real-time qPCR could not be used.
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retroelements. By using a cell-based ex vivo assay, we have
shown that APOBEC3G dramatically inhibits retrotransposi-
tion of murine IAP and MusD elements, and induces G-to-A
hypermutations in their transposed DNA copies. The assay
used retroelements marked with a neo-containing indicator
gene that becomes active only after retrotransposition, and
subsequent selection of the resulting G418-resistant cells
(10,11,22,59,60). To determine whether the observed decrease
in the retrotransposition rate is only due to proviral cDNA
editing per se acting at the level of the neo gene, or whether
it is additionally the consequence of a decrease in the number
of integrated copies, we presently measured the copy number
of transposed MusD, IAP and control L1 elements, using a
reﬁned quantitative PCR (qPCR) method, in the absence of
any selection. We show that APOBEC3G has a dual effect on
endogenous retroviruses, resulting ﬁrstly in a decrease of the
number of transposed copies and secondarily in extensive
editing of the transposed copies. The effects of other members
of the cytosine deaminase family on the retrotransposition of
murine retroelements are also examined.
MATERIALS AND METHODS
Plasmids
Expression plasmids containing the mouse MusD
(pCMVMusD-6neo
TNF), mouse IAP (pGL3-IAP92L23-
neo
TNF) and human L1 (p220.CMV-L1.2Bneo
TNF) retrotrans-
posons have been described previously (10,11,61). The hA3G
and mA3 expression plasmids used were a gift from A. Hance
and N. Landau, respectively. The AID, hA1, hA2, hA3B,
hA3C, hA3F and agmA3G expression plasmids were obtained
through the NIH AIDS Research and Reference Reagent pro-
gram (45,57). All the APOBEC open reading frame containing
fragments were re-cloned in pcDNA6 expression plasmid
(Invitrogen).
Cells, transfection and retrotransposition assay
Human HeLa cells were grown in DMEM containing
Glutamax I and sodium pyruvate (Invitrogen) and supple-
mented with 10% fetal calf serum (Gibco BRL), 100 mg/ml
streptomycin and 100 U/ml penicillin. HeLa cells (3 · 10
5),
seeded in 60 mm diameter plates, were transfected with 1.5 mg
neo
TNF-marked retrotransposon and 1.5 mg cytosine deami-
nase expression vector by using the Lipofectamine Plus kit
(Gibco BRL). Two days post-transfection, two-thirds of the
cells were recovered for RNA and DNA analyses (see below);
the remaining one-third was maintained in culture for 1 week,
andcellswere thenseededat3 · 10
5cellsper100mmdish for
G418 selection. After 14 day selection, G418
R foci were ﬁxed,
stained and counted.
Nucleic acid extractions and quantifications
Cellular DNA from the transfected cells was extracted as
described elsewhere (59) and was used as a template for spe-
ciﬁc PCR ampliﬁcation of the spliced neo
TNF domain. PCR
ampliﬁcation was performed using the forwardprimer 50-CAG
TTC GGC TGG CGC GAG GCC-30 and the reverse primer
50-CAG TTC CGC CCA TTC TCC G-30 in 50 ml containing
0.5mg of cellular DNA, 1· Buffer II and 1.5 U AccuPrime Taq
DNA polymerase (Invitrogen), with an initial denaturation
step at 94 C (3 min) followed by at least 30 cycles of amp-
liﬁcation (50 s at 94 C, 50 s at 60 C and 1 min at 68 C). PCR
products were electrophoresed on agarose gels in the presence
ofethidium bromide (1mg/ml) andquantiﬁed by densitometry,
using the Kodak 1D Image Analysis Software (Kodak). For
qPCR (see Results), 5 ml aliquots were removed from the PCR
mixture at each of the 10 last cycles, and analyzed as above. A
regression equation y ¼ a · b
n (where y is the intensity of the
band, n the cycle number, a the template amount, and b
the efﬁcacy of ampliﬁcation per cycle) was ﬁtted to the
data in the linear portion of the ampliﬁcation reaction
curve. In some experiments, the PCR products were elec-
trophoresed on agarose gels, puriﬁed with the Nucleospin
Extract II kit (Macherey-Nagel) and cloned into pGEM-T
easy vector (Promega). After transformation of DH5a
cells, 20–25 clones were sequenced (Applied Biosystem
sequencing kit) to determine the editing potency of each cyto-
sine deaminase.
Total RNA was extracted from transfected cells with the
Nucleospin RNA II kit (Macherey-Nagel). RNA (1 mg) was
reverse transcribed in a 20 ml volume reaction using 50 U
Moloney murine leukemia virus reverse transcriptase (Perkin
Elmer Applied Biosystems), 20 U RiboNuclease inhibitor
(Applied Biosystems), 1 mM dA/T/G/C (Amersham-
Pharmacia Biotech), 5 mM MgCl2, 10 mM Tris–HCl (pH
8.3), 10 mM KCl and 2.5 mM random hexamers (Applied
Biosystems). After an initial primer-annealing step at room
temperature for 10 min., reverse transcription was performed
at 42 C for 45 min and ended by heating at 99 C for 7 min.
qRT–PCR was then carried out with 1 ml of the RT-treated
sample using the same PCR conditions as above.
RESULTS
Rationale of the assay for retrotransposition
We have used the previously described neo-marked MusD and
IAP retroelements to assay the effects of APOBEC cytosine
deaminases on the retrotransposition of these elements. The
rationale of the experiment is illustrated in Figure 1A, and
includes (i) transfection of the marked retroelement in the
presence—or not—of an expression vector for the APOBEC
proteins, (ii) extraction of total RNA from a fraction of the
cells two days post-transfection to assay for possible effects
of the APOBEC proteins on retroelement transcript levels, (iii)
plating of the cells for selection in G418-containing medium,
to assay for the rate of retrotransposition, via measurement
of the number of G418-resistant (G418
R) clones and, in par-
allel (iv) DNA extraction from a fraction of the cells before
selection, totentativelymeasureby direct methods (seebelow)
the extent of retroelement transposition in the absence of
any selection. For the latter measurement, we took advantage
of the presence within the marked retroelements of an intron
inserted into the neo gene, which is spliced out during the
retrotransposition process [also resulting in the activation of
the neo gene and survival of the cells with retrotransposed
elements in G418-containing medium, feature used for assay
(iii) above] (22,59,60). Speciﬁc primers for the ampliﬁca-
tion of the spliced neo gene in the retrotransposed copies
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junction within the neo gene (Figure 1B), in order to minimize
the ‘parasitic’ ampliﬁcation of the vast excess of non-
transposed neo-marked plasmid copies present in the trans-
fected cells (retrotransposition frequency is at most 10
 3 event
per cell, i.e. DNA copies with a spliced out intron are about
3 logs less numerous than the parental marked copies). How-
ever, even with these primers and a Taq polymerase enzyme
with improved priming accuracy (AccuPrime Taq, Invitro-
gen), several bands were detected in the PCR ampliﬁcation
product of the genomic DNA from cells with transposed ele-
ments (see Figure 1C and legend). Sequencing demonstrated
that the 643 bp species corresponded to the product expected
for spliced, transposed neo-marked copies, whereas the 725 bp
species corresponded to the background PCR ampliﬁcation
of unspliced, non-transposed copies of the marked retroele-
ments. Other bands were occasionally observed, with a vari-
able intensity depending on the transfection experiment—and
not on the presence of the APOBEC expression vectors—that
were found to correspond to either alternative splicing
events (for the <643 bp bands) or unexpected structures
(for the high molecular weight band) due most probably to
recombination events between transfected plasmid DNA
molecules. This precluded the use of standard real-time
qPCR methods. We therefore devised a manual, indirect
method in which an aliquot was removed at each cycle
of the PCR, the products separated by agarose gel electrophor-
esis and the intensity of the 643 bp band quantiﬁed by
densitometry. As illustrated in Figures 1C and 2, a plot of
the intensity of the speciﬁc band as a function of the PCR
cycle number yielded sigmoı ¨d curves, similar to those
obtained in real-time qPCRs with an intermediate phase dis-
closing a sharp increase corresponding to the linear range of
the ampliﬁcation reaction, i.e. where the amount of ampliﬁed
fragment was proportional to the input amount of target DNA.
Based on a ﬁt of this linear portion of the graphs (see logar-
ithmic representation in inset of Figure 1C), we established
that the efﬁcacy of ampliﬁcation was 1.75-fold per PCR cycle,
satisfactorily close to the theoretical value of 2 for optimal
PCR ampliﬁcations (see Materials and Methods).
APOBEC3G reduces the amount of transposed MusD
and IAP elements
Using this PCR assay, it can be clearly shownthat the presence
of hA3G signiﬁcantly reduced the copy number of transposed
MusD and IAP elements (Figure 2). We observed a signiﬁcant
difference in the number of PCR cycles (up to 5 cycles for
MusD and 2 cycles for IAP) required to reach similar ampli-
ﬁcation levels. Quantitatively, this difference corresponds
to a 10- to 20-fold and a 2- to 3-fold decrease in MusD and
IAP cDNA levels, respectively (Figure 2A). This effect actu-
ally closely correlates with the results obtained in the standard
retrotransposition assay using G418 selection, with a 50-fold
and a 4-fold decrease in the number of G418
R clones for each
of these two retrotransposons, respectively [Figure 3A and see
Ref. (22)]. The transposed copy number of a control non-LTR
LINE retroelement (L1) was not affected by the presence of
hA3G (Figure 2A), in agreement with the previous observa-
tions that L1 elements are insensitiveto hA3G activity (22,62).
To rule out a possible effect of hA3G on the efﬁciency of the
PCR assay per se due to, for instance, decreased matching of
the primers used for the PCR as a result of the editing activity
of hA3G on the DNA template, we performed a series of
controls, using other sets of primers and/or primers with
degenerate nucleotides at the positions prone to the editing
effect (Supplementary Figure S1). The results obtained with
such primers disclosed an identical level of reduction in the
amount of retrotransposed copies generated in the presence of
hA3G. Altogether, the present results clearly indicate that
APOBEC3G has an effect on the number of transposed copies
of endogenous retroviruses, independently of any ‘selection’
procedure. The slightly higher reduction levels observed when
measuring the G418
R clone number could simply be
accounted for by a mutagenic inactivation of the neo gene
in some of the transposed copies, resulting in the loss of
the corresponding cells upon G418 selection.
We next asked whether the reduction in the number of
MusD and IAP transposed copies by APOBEC3G could be
related to a decrease in the level of viral RNA templates. To
this end, we applied our quantitative PCR method to cellular
RNAs prepared two days after transfection and reverse tran-
scribed in vitro. As illustrated in Figure 2B, hA3G did not
affect the level of the detected MusD, IAP or L1 transcripts,
with the neo intron spliced out.
Conclusively, these results demonstrate that hA3G
reduces the amount of retrotransposed copies. This inhibitory
effect does not take place at the viral RNA level but during or
after reverse transcription, most probably via deamination (see
below) and subsequent degradation of the nascent viral
cDNAs.
‘Anti-viral’ effects of other members of the
APOBEC family
We then investigated the effect of other members of cytosine
deaminase family on the retrotransposition of the MusD
retroelement. We tested human AID (hAID), APOBEC1
(hA1), APOBEC2 (hA2) and APOBEC3B, APOBEC3C,
APOBEC3G and APOBEC3F (hA3B, hA3C, hA3G and
hA3F) family members. hA3G is the ﬁrst cytosine deaminase
that was demonstrated to have an antiviral activity, hA3F was
then shown to be active against HIV, whereas hA3B only
modestly affects HIV and SIV, and hA3C has antiviral activity
only against SIV (41,42). The African green monkey
APOBEC3G (agmA3G) and murine APOBEC3 (mA3) pro-
teins, which have been demonstrated previously to display a
potent anti-retroviral activity (51,57,63), were also included in
the assay. HeLa cells were co-transfected with the marked
MusD element and an expression vector for each of these
proteins. Cells were then analyzed as above, both by G418
selection and by qPCR.
Three groups of APOBEC proteins could be distingui-
shed, according to their anti-MusD activity (Figure 3). The
ﬁrst group corresponds to efﬁcient anti-retroviral proteins
(hA3G, hA3F, agmA3G and mA3) which induced a decrease
in the number of G418
R clones of 50-, 5-, 6- and 5-fold,
respectively. The second group includes hAID, with only a
modest—but reproducible—2-fold reduction effect on MusD
retrotransposition. The third group corresponds to non-
inhibitory proteins (hA1, hA2, hA3B and hA3C). Analysis
of the amount of retrotransposed MusD copies by qPCR
Nucleic Acids Research, 2006, Vol. 34, No. 5 1525provided consistent results (Figure 3B), with a similar rank
order for the effect of the various cytosine deaminases
tested and, as already noticed in the previous section for
APOBEC3G, a slightly smaller magnitude of the reduction-
most probably associated with the editing of the neo gene
which enhances the inhibitory effect in the G418 selection
assay.
Differential editing of the retrotransposed elements
by various cytosine deaminases
We then analyzed the editing potency of the various APOBEC
proteins on a fragment of the retrotransposed MusD elements
recovered by direct PCR, without prior G418 selection of
the cells. For each APOBEC protein, 643 bp neo-containing
PCR fragments were cloned, and at least 20–25 different
sequences determined. As illustrated in Figure 4, we observed
a high number of mutations in the presence of hA3G, hA3F,
agmA3G, mA3 and hAID, i.e.  104, 55, 21, 61 and 23 muta-
tions per 10000 bases analyzed, respectively. Furthermore,
a large majority of the mutations were G-to-A transitions
(93% for hA3G, 88% for hA3F, 68% for agmA3G, 81% for
mA3 and 53.5% for hAID), with the other substitutions ran-
domly distributed (Figure 4A). The distribution of the G-to-A
substitutions per individual 643 bp sequence ranged from
none to up to 36 (see histograms in Figure 4A), and the overall
mutation rate was rather high, reaching a mean of eleven
mutations per MusD-derived 643 bp fragment in the case of
hA3G, consistent with the results obtained previously with
the same enzyme, but following prior selection of G418
R
Figure2. EffectsofhA3GontheamountofMusD,IAPandL1transposedcopiesandintermediateRNAs.(A)QuantitativeanalysisoftheeffectsofhumanhA3Gon
the number of retrotransposed MusD, IAP and L1 neo-marked elements. HeLa cells were transfected with 1.5 mg of the indicated marked retrotransposon, in the
presence or absence of 1.5 mg of hA3G expression vector. DNA was extracted 2 days post-transfection, and PCR was carried out with 0.5 mg of cellular DNA. The
resultsarerepresentedasinFigure1C,withthebandoftheexpectedsize(643bp)fortheretrotransposedcopiesindicatedwithblackarrowheads.Datapointsinthe
intensity/cycleplotsarethemeansofduplicatedeterminations,andeachcurveisrepresentativeofatleastthreeindependentexperimentswithameanfoldreduction
of13.6 ± 3.4forMusD(n ¼ 5),3.4 ± 1.5forIAP(n ¼ 3)andnosignificantdifferenceforL1(n ¼ 3).(B)hA3Ghasnoeffectontheretroelementtranscriptlevels.
RNAswereextracted2dayspost-transfectionfromthesamecellpopulationsasin(A)andreversetranscribedinvitro.QuantificationofthecDNAswasperformedas
in (A). Data points in the plots are the means of duplicate determinations and the curves are representative of two independent experiments.
1526 Nucleic Acids Research, 2006, Vol. 34, No. 5cells (22). It is noteworthy that, in agreement with previous
reports (22,64,65), a large fraction of the G-to-A mutations
occurred in the typical GG dinucleotide context (at
the underlined nucleotide) for hA3G and agmA3G (up to
71 and 79%, respectively), GA dinucleotide context for
hA3F (up to 62%) and GXA trinucleotide context for mA3
(up to 66%) (Figure 4C). For hAID, no clear-cut sequence
speciﬁcity could be unraveled. For hA1, hA2, hA3B and
hA3C, as expected from the retrotransposition assay, only
few mutations were observed, which further appeared to be
random (Figure 4A and B).
DISCUSSION
Despite profound similarities between infectious retroviruses
and endogenous LTR retroelements, which relate to their
common ancestral history, the ‘physiological’ impact of
both classes of elements are different. Indeed, the primary
‘goal’ of infectious retroviruses is to replicate in the host,
i.e.remainfunctionalasaninvadingelement,whereasendoge-
nous retroelements are already present within the host genome
as multicopy ‘genes’ most of which are inactive. Although
the difference is tenuous, it may explain why the recently
discovered effects of the ancestral cellular cytosine deami-
nases on infectious retroviruses have mainly concerned
their editing potency, which renders them defective for further
replicative cycles and propagation. This editing potency also
applies in the case of endogenous elements. Indeed, it has been
recently demonstrated that several LTR retroelements are sub-
jected to editing by the APOBEC3G enzyme, as illustrated
both by using retrotransposition assays [for Ty1 see Refs.
(23,24) and for mammalian retrotransposons Ref. (22)] and
by performing an in silico search for traces of the expected
mutations within the numerous copies of these elements that
have been generated in the course of genome evolution and
retroelement expansion (22). Yet, the effect of cytosine
deaminases on the amount of proviral copies—edited or
not—that are generated by functional endogenous retrotrans-
posons remains an essential parameter for their mobility and
their resulting potential for insertional mutagenesis.
The present study, therefore, is an important step in the
characterization of the effects of cytosine deaminases and
of their impact as defense enzymes against these elements.
By using an appropriate PCR-based quantiﬁcation method,
we demonstrate that the human APOBEC3G actually reduces
the number of retrotransposed copies of the MusD and IAP
retrotransposons, by 10- to 20-fold and 2- to 3-fold, respec-
tively. We show that this reduction is not due to an effect of
the cytosine deaminases on the transcript levels of the marked
retroelements. Sequencing of the rescued retrotransposed
copies further demonstrates editing of the proviral DNA, a
process which most probably takes place during reverse
transcription of the IAP and MusD transcripts. Although
one cannot formally exclude that cytosine deaminases inhibit
the reverse transcription process per se, it is likely that the
observed decrease in the amount of proviral DNA is due to a
degradation of the deaminated reverse transcripts, prior to
integration [for HIV-1 see also Refs. (38,57) and for Ty1
(23)]. Cellular DNA repair enzymes such as uracil-DNA
glycosylases could be responsible for this degradation (66)
Along this line, it is noteworthy that preliminary experiments
that we carried out using mutants in the catalytic domain of
hA3G [i.e. the M2 (23) and the E259Q (67) mutants] disclosed
areversionoftheinhibitoryeffect onMusDretrotransposition.
Altogether, the present results show that APOBEC enzymes
have a dual effect on endogenous retroviruses (Figure 5): they
reduce the number of proviral copies that are generated by the
IAP and MusD marked elements, and they have an editing
activity which results in the introduction of mutations into
the transposed copies. The latter effect is important since
mutations can indeed inactivate the newly integrated copies,
render them defective for autonomous retrotransposition and
cut short additional retrotransposition cycles, but most proba-
bly the primary ‘line of defense’ against retroelements is
mediated by the former effect, which reduces the number
of transposed copies whose integration can directly mediate
insertional mutagenesis.
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Figure 3. Differential effects of cytosine deaminases on the retrotransposition
of MusD. Analysis of the effect of human hA3G, hAID, hA1, hA2, hA3B,
hA3C, hA3F, African green monkey agmA3G and murine mA3 on MusD
retrotransposition. (A) Measurement of the number of G418
R clones after
selection in G418-containing medium of the cells co-transfected with the
marked MusD and the expression vector for the indicated cytosine deaminase;
values are given as the percentages of the corresponding values obtained in the
absence of cytosine deaminase expression vector (no APO). Data are the
means ± SD of at least three independent experiments. (B) Quantitative ana-
lysis as in Figure 2 of the number of retrotransposed MusD copies, in the
absence of G418 selection. DNA was extracted from cells transfected as in
(A).Valuesoftheintensityofthespecific643bpPCRfragment,measuredafter
30 cycles of amplification, are expressed as the percentages of the correspond-
ing values in the absence of cytosine deaminase. Data points are the
means ± SD of at least three independent experiments.
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1528 Nucleic Acids Research, 2006, Vol. 34, No. 5Another outcome of the present study is the demonstration
that several—but not all—APOBEC proteins have the capac-
ity to restrict retrotransposition of LTR retroelements in cell
culture experiments, with a dual effect. Consistently, the
human hA3G protein efﬁciently inhibits retrotransposition
of MusD retrotransposons and induces G-to-A hypermutations
in their genomes, and the human hA3F, simian agmA3G and
murine mA3 proteins are also strongly active. Interestingly,
the human and simian APOBEC3G proteins target the same
expected consensus site for the G-to-A substitutions, namely
the GG dinucleotide, whereas the human hA3F and the
murine mA3 proteins disclose G-to-A mutations in the GA
dinucleotide and GXA trinucleotide, respectively, in agree-
ment with previous reports (41–44). Interestingly, we show
here that the human hAID protein displayed a limited—but
reproducible—effect on the rate of MusD retrotransposition,
and induced a small number of mutations in the transposed
copies. The AID protein is known to edit immunoglobulin
gene DNA, and thus to function in the nucleus. However,
AID is a nucleocytoplasmic shuttling protein and is also
partly localized in the cytoplasm (68–70). This may explain
the limited effects of hAID on MusD retrotransposition.
Whether this unexpected activity of hAID on endogenous
retroviruses is of physiological relevance awaits further anal-
ysis. Similarly, differences in subcellular localization and/or
intrinsic enzymatic activities might account for the absence
of effect that we observed for the hA3B and hA3C proteins, as
well as for the two other APOBEC family members tested
(hA1 and hA2).
Finally, it is noteworthy that in the case of the most active
APOBEC protein, we found that the murine MusD LTR
retroelement is sensitive to the human, simian and murine
enzymes (hA3G, agmA3G and mA3), without signiﬁcant
species-speciﬁc differences. This strong functional conserva-
tion is most probably relevant to the primary role of this
APOBEC protein as a defense mechanism, against elements
that are extremelydiverse even within agiven species, with for
example more than a hundred distinct families of endogenous
retroviruses in the human genome. This diversity, resulting
from the repetition of ‘invasions’ during species evolution, has
most probably imposed, at the level of the eukaryote genomes,
the conservation of a guardian gene with a large spectrum
of action, and concomitantly, at the level of the genomes of
emerging retroviruses, the invention of reﬁned counteracting
strategies.
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